• 대한기관윤리심의기구협의회지
• /
• 제3권1호
• /
• pp.1-10
• /
• 2021

In 2004, India began investing in the clinical trial industry; the country now boasts a 20% market share with the help of a valuable resource - the world's second largest population. The Contract Research Organization has been able to generate profits efficiently conducting clinical trials via a large pool of participants, skilled researchers, and reduced developmental costs. As the demand and sheer number of global clinical trials increased, the International Council of Harmonization-Good Clinical Practice was introduced, and the need for the Institutional Review Board increased. While the clinical trial industry in India boomed, it came at the expense of the participants' civil rights. The increased media attention regarding the ethical issues forced the Indian Supreme Court to take action. Consequently, India is the only country, by law, that specifically compensates participants suffering from injury directly resulting from participation in clinical trials. This research paper will describe and compare the relevant laws of India and Korea including compensation criteria. In addition, the ethical issues and aspects of indemnity in clinical trials will be discussed. While the clear advantage of the compensation is one of the protected rights of a clinical subject, the current system is not perfect. Furthermore, laws created to redeem ethical issues can have unintended, negative consequences.

• 한국임상약학회지
• /
• 제26권1호
• /
• pp.77-83
• /
• 2016

Background: Oversight on the bioethical compliance of national R&D projects or research personnel is currently conducted exclusively by IRB (Institutional Review Board) within the relevant research institute. Considering current state of affairs in Korea, there is an imperative to establish a national oversight system for bioethical compliance, conduct comprehensive oversight on bioethical compliance of national R&D projects, and enhance subject protection system. Methods: We examined opinions from researchers and IRB personnels regarding ethical oversight system on R&D projects. Additionally, we looked at IRB assessment by KAIRB (Korea Association of Institutional Review Board) in order to identify status and problems with current IRB system in Korea. Assessment was also done for four other countries (US, UK, Germany, Singapore) through in-person visits as well as surveys in writing for a total of 6 months (2012.12.1~2013.5.31). The research comprised of two aspects: system management and R&D project audit. Based on this, we examined current status and problems of the existing system in Korea and made recommendations for improvement. Results: Regulatory objectives and backgrounds of biomedical researches are different from each country due to different characteristics of bioethical oversight system. This shows that each country sets up its own regulations and procedures to fit each situation. Bioethical compliance oversight system greatly varied between the countries. From this study, it can be seen that improvement of existing procedures and oversight system or establishment of new ones are essential in Korea. Conclusion: In terms of system management, a dedicated government organization need to be established for bioethical compliance, subject protection, IRB inspection, training, evaluation, and certification of systems, and also support for IRB e-system. Regarding R&D project oversight, it is essential to confirm IRB review results before start of a research, to conduct a review on ethical aspects of research plans, and to carry out continued oversight on bioethical compliance through interim reports.

• Obstetrics & gynecology science
• /
• 제61권6호
• /
• pp.693-697
• /
• 2018

Aggressive angiomyxoma (AA) is a very rare mesenchymal tumor most commonly found in the pelvic and perineal regions. For the complete excision of retrorectal tumors, with extension through the levator muscle into the ischioanal space, open anterior and posterior approaches are typically required. Herein, we report our experience with robotic excision of a giant presacral AA with extralevator extension into the ischioanal space and extraction via Pfannenstiel incision, which we found to be technically feasible, efficacious, and safe to perform. Mayo Clinic Institutional Review Board exemption status was obtained for this study.

• 보건행정학회지
• /
• 제33권3호
• /
• pp.241-242
• /
• 2023

As part of efforts to internally strengthen the research ethics capacity of the Korean Academy of Health Policy and Management, we have compiled research ethics issues that are frequently encountered in public health researches. Firstly, when reusing research reports or dissertations as papers, efforts should be made to avoid unfair duplicate publication. Compliance with the institutional review board exemption process is required, and additional efforts should be devoted during the text recycling process to prevent self-plagiarism or unjust duplicate publication.

• 의료법학
• /
• 제19권1호
• /
• pp.165-206
• /
• 2018

연구와 관련하여 다중적 이해관계(multiple interests)를 가지고 있는 연구자, 기관생명윤리위원회 및 임상시험심사위원회 위원, 연구기관 등은 전문적인 판단(professional judgment)을 내림에 있어 이해상충(Conflicts of Interest)의 문제가 발생하지 않도록, 즉 자신이 수행해야 하는 역할이나 이행해야 하는 의무에 의하면 반드시 고려되어야만 하거나 보다 우선시되어야하는 1차적 이해(primary interest)가 그렇지 않은 2차적 이해(secondary interest)로 인해 영향을 받지 않도록 하여야 한다. 그러므로 이해상충의 문제의 발생을 예방하거나 발생된 이해상충의 문제를 해결할 수 있도록 하기 위해 기준과 방법이 마련되어 있어야 하고, 이와 관련한 기본적인 사항은 모든 당사자가 이해하고 따를 수 있도록 하기 위해 법정책적으로 명확하게 제시될 필요가 있다. 보다 현실성 있는 법정책의 마련을 위해서는 현황 파악이 전제되어야 할 것이므로 연구 관련 주요 실무자인 기관생명윤리위원회 및 임상시험심사위원회의 운영지원인력(행정간사)을 대상으로 하여 수행된 설문조사 및 인터뷰의 결과를 살펴봄으로써 이해상충과 관련한 법정책적 쟁점과 이의 해결을 위한 대응방안에 관한 의견을 확인해보았다. 그리고 향후 이해상충에 대한 국내 법정책의 마련에 도움을 주고자 미국 보건부에서 발표한 이해상충 관련 지침의 주요 내용을 살펴보았다. 마지막으로, 이해상충과 관련한 국내 법정책의 현황을 연구자의 이해상충, 기관생명윤리위원회 및임상시험심사위원회위원의 이해상충, 기관의 이해상충으로 구분하여 파악해보고 그 개선방안을 제시하였다.

• 대한핵의학회지
• /
• 제38권2호
• /
• pp.140-142
• /
• 2004

As a molecular imaging is the most up-to-date technology in Nuclear Medicine, it has complicate ethical and regulatory problems. For animal experiment, we have to follow institutional animal care committee. for clinical experiment, we have to get approval of Institutional Review Board according to Helsinki declaration. In addition, approval from Korea Food and Drug Administration (KFDA) is essential for manufacturing and commercialization. However, too much regulation would suppress development of new technology, which would result in the loss of national competitive power. In addition, most new radioactive ligands for molecular imaging are administered to human at sub-pharmacological and sub-toxicological level. In conclusion, a balanced regulation is essential for the safety of clinical application and development of new technology.

• 대한기관윤리심의기구협의회지
• /
• 제4권2호
• /
• pp.30-35
• /
• 2022

The Human Research Protection Program (HRPP) includes all subject protection activities and entities involved in the process of planning, reviewing, and conducting clinical research and it ultimately aims that research can be conducted ethically and scientifically while protecting the rights and welfare of research subjects. At the beginning of its introduction in Korea, it was settled down by adopting the United States HRPP, especially the form of AAHRPP element and regulations. However, regulations and operating forms of HRPP have been changed according to the Korean domestic research environment. Actually, all the Korean institutions are adopted the Korean HRPP guidelines that have been officially announced by the Ministry of Food and Drug Safety in Korea. Recently, Korean domestic laws such as the "Advanced Regenerative Biology Act" or "In Vitro Diagnostic Medical Device Act" have been dramatically innovated and our research environment becomes to be more complicated. Therefore, the development of a suitable Korean HRPP model considering the Korean research environment is strongly demanded. For the early settle down of the Korean HRPP model, the positive incentive method should be applied, when the HRPP is operated and/ or properly operated. These improvements in the Korean HRPP environment will eventually lead to the appropriate protection of subjects who are participating in human clinical research and the quality improvement of clinical research.

• Journal of Yeungnam Medical Science
• /
• 제35권1호
• /
• pp.36-39
• /
• 2018

In the personalized medicine era, utilizing paraffin blocks in pathology archives for investigating human diseases has come into the limelight. This archived material with clinical data will reduce the research time and could prevent new patient recruitment to obtain tissue for research. However, the clause indicating the necessity of consent from human material providers in the Korean Bioethics and Safety Act has made the Institutional Review Board (IRB) deny permission to use paraffin blocks for research without consent, and alternatively to get the same before starting an experiment. Written consent may be waived off in studies using paraffin blocks with anonymous status or conditions not linked to personal information by applying the paragraph 3, article 16 of the current Bioethics and Safety Act. Also, the IRB should recommend researchers to preserve the blocks as medical records of patients in long-term archives.

• 한국보육지원학회지
• /
• 제14권2호
• /
• pp.1-17
• /
• 2018

Objective: The purpose of this paper is to understand the bioethics and the Institutional Review Board (IRB) in the social and behavioral research area through "The Bioethics and Safety Act" and to examine the IRB's present situation, roles, responsibilities, and tasks. Methods: This paper reviewed articles, materials for education, and "The Bioethics and Safety Act" related with the IRB. Results: Bioethics included all the research in the social and behavioral area, and "The Bioethics and Safety Act" has been enforced in every research projects targeting human subjects since February 2, 2013. Accoding to the law, the IRB must review the research proposals for human subjects and was introduced in social and behavioral research as a self-regulating system. At present, all the related institutions including universities must establish and run the IRB. This paper introduced the definition of bioethics, the IRB's roles and review types, the total number of registered IRB, and "The Bioethics and Safety Act". Conclusion/Implications: Both the central government and the local government have to make an effort for the establishment and settlement of the IRB system. This paper also presented some of the problems of the IRB.

• 보건교육건강증진학회지
• /
• 제28권3호
• /
• pp.113-128
• /
• 2011

Objectives: The purpose of this study was to investigate the current state and trends of health-related research on foreign migrants living in Korea. Methods: Among 85 articles identified via PubMed and RISS and additional 7 articles by ancestry search, 28 were selected for the review. Two authors independently reviewed the articles using a literature review matrix and examined together the three aspects of the studies: research methods, research topics, and research results. Results: Most of the articles were published between 2005-2009, and only 3 studies used an interdisciplinary approach. Most were exploratory and there were 4 intervention studies: three of them examined the effect of an art therapy on acculturative stress and mental health among marriage migrant women. The lack of information on informed consent, approval of institutional review board, and the validity/reliability of the translated instruments were noted. Conclusions: Research is needed to examine migrants' health behaviors, the prevalence of chronic illness among migrants, and the influence of acculturation on the use of health resources, health behaviors, and health status. Researchers should be aware of ethnic issues when they work with foreign migrants.